BioSyent to Attend Planet MicroCap Showcase
23 avr. 2024 17h45 HE
|
BioSyent Inc.
MISSISSAUGA, Ontario, April 23, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that it will be attending the Planet MicroCap Showcase in Las Vegas,...
BioSyent Announces Extension of RepaGyn® and Proktis-M® Agreement
15 avr. 2024 16h31 HE
|
BioSyent Inc.
MISSISSAUGA, Ontario, April 15, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its wholly-owned subsidiary, BioSyent Pharma Inc....
BioSyent to Present at 2024 Bloom Burton & Co. Healthcare Investor Conference
10 avr. 2024 08h30 HE
|
BioSyent Inc.
MISSISSAUGA, Ontario, April 10, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that it will be presenting at the upcoming 2024 Bloom Burton &...
FeraMAX® est la marque de supplément de fer que les pharmaciens et les médecins au Canada recommandent le plus souvent depuis neuf années consécutives
03 avr. 2024 08h00 HE
|
BioSyent Inc.
Mississauga (Ontario), 03 avr. 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (« BioSyent », titre à la Bourse de croissance TSX : RX) est fière d’annoncer que FeraMAXMD est la marque de supplément de fer...
FeraMAX® Named #1 Recommended Iron Supplement in Canada by Pharmacists and Physicians for Ninth Consecutive Year
03 avr. 2024 08h00 HE
|
BioSyent Inc.
MISSISSAUGA, Ontario, April 03, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that FeraMAX® is the #1 recommended iron supplement brand in Canada, based...
BioSyent to Present at LD Micro New York Investor Conference
01 avr. 2024 14h00 HE
|
BioSyent Inc.
MISSISSAUGA, Ontario, April 01, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent” or the “Company”, TSX Venture: RX) announces that Mr. René Goehrum, President and CEO of BioSyent, will be...
BioSyent Announces Grant of Restricted Share Units
27 mars 2024 18h34 HE
|
BioSyent Inc.
MISSISSAUGA, Ontario, March 27, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent” or the “Company”, TSX Venture: RX) announces that its Board of Directors has approved a grant of 66,020...
BioSyent Releases Financial Results for Fourth Quarter and Full Year 2023
13 mars 2024 17h30 HE
|
BioSyent Inc.
MISSISSAUGA, Ontario, March 13, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the fourth quarter (Q4) and full year (FY) ended...
BioSyent Schedules Fourth Quarter and Full Year 2023 Earnings Release for March 13, 2024
06 mars 2024 16h30 HE
|
BioSyent Inc.
MISSISSAUGA, Ontario, March 06, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three months and full year ended...
BioSyent Named to 2024 TSX Venture 50
21 févr. 2024 08h00 HE
|
BioSyent Inc.
MISSISSAUGA, Ontario, Feb. 21, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that it has been named to the 2024 TSX Venture 50 list as...